Smith & Nephew plc (NYSE:SNN) Shares Purchased by Citigroup Inc.

Citigroup Inc. increased its position in shares of Smith & Nephew plc (NYSE:SNN) by 18.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 119,215 shares of the medical equipment provider’s stock after buying an additional 18,630 shares during the period. Citigroup Inc.’s holdings in Smith & Nephew were worth $3,712,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNN. River Road Asset Management LLC purchased a new stake in Smith & Nephew during the 3rd quarter worth $38,588,000. Bank of Montreal Can grew its holdings in Smith & Nephew by 355.8% during the 2nd quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock worth $31,059,000 after acquiring an additional 964,762 shares in the last quarter. Brandes Investment Partners LP grew its holdings in Smith & Nephew by 20.5% during the 2nd quarter. Brandes Investment Partners LP now owns 1,373,051 shares of the medical equipment provider’s stock worth $34,002,000 after acquiring an additional 233,293 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Smith & Nephew by 58.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock worth $12,995,000 after acquiring an additional 193,046 shares in the last quarter. Finally, Deprince Race & Zollo Inc. grew its holdings in Smith & Nephew by 94.2% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 239,245 shares of the medical equipment provider’s stock worth $5,928,000 after acquiring an additional 116,078 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

NYSE SNN opened at $25.30 on Thursday. Smith & Nephew plc has a one year low of $23.65 and a one year high of $31.72. The company has a 50-day simple moving average of $27.28 and a 200-day simple moving average of $27.88. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63.

Analyst Ratings Changes

Several research analysts have weighed in on SNN shares. Berenberg Bank lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. StockNews.com lowered shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, November 1st.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.